Comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 vs 16p12 2 Microdeletion Syndrome C4708497
Clinical comparison between 3 Beta Hydroxysteroid Dehydrogenase Deficiency and 16p12 2 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
A rare genetic disorder affecting adrenal hormone production. It can cause ambiguous genitalia, salt-wasting crises, and hormonal imbalances. Treatment requires hormone replacement therapy and careful monitoring.
16p12 2 Microdeletion Syndrome C4708497
A rare genetic condition where a small piece of chromosome 16 is missing. It can cause developmental delays, intellectual disability, and recurrent infections in some individuals. Treatment involves supportive therapies and medical management of symptoms.
6 comparison axes
Onset
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
0-null
16p12 2 Microdeletion Syndrome C4708497
0-5
Onset patterns differ
Severity
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
severe
16p12 2 Microdeletion Syndrome C4708497
moderate
Different severity levels
Chronic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Chronic
16p12 2 Microdeletion Syndrome C4708497
Chronic
Differing course
Communicable
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
No
16p12 2 Microdeletion Syndrome C4708497
No
Different transmission
Body System
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
16p12 2 Microdeletion Syndrome C4708497
congenital
Same/different system
Category
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
16p12 2 Microdeletion Syndrome C4708497
genetic
Different category
Bottom line
3-beta-hydroxysteroid-dehydrogenase-deficiency-C0342471 and 16p12-2-microdeletion-syndrome-C4708497 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 16p12 2 Microdeletion Syndrome C4708497 | Discriminating power |
|---|---|---|---|
| Salt-wasting crisis | May present in infancy with vomiting, dehydration, and low sodium; not universal. | Not a described core feature of the microdeletion. | High |
| Genital development | Ambiguous or atypical genitalia may occur from disordered steroid synthesis. | Not established as a characteristic finding. | Moderate |
| Developmental delay | Not the defining feature; neurologic effects are not established here. | Developmental delay or intellectual disability may occur and vary widely. | Moderate |
When to favor each condition
Choose 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 when
Infant with suspected adrenal crisis
Steroid-synthesis disorder better explains salt wasting and hormone imbalance.
High
Atypical genitalia with endocrine clues
Adrenal and gonadal steroid disruption is central to this condition.
Moderate
Abnormal steroid profile
Pattern may support targeted endocrine and genetic evaluation.
Moderate
Choose 16p12 2 Microdeletion Syndrome C4708497 when
Developmental delay with dysmorphic or congenital clues
A chromosomal microdeletion is more consistent than an adrenal enzyme defect.
Moderate
Recurrent infections without adrenal crisis
Infections are described in some people with the microdeletion.
Low
Chromosomal microarray abnormality
A confirmed 16p12.2 deletion directly supports this diagnosis.
High
How key tests differ
| Test | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 16p12 2 Microdeletion Syndrome C4708497 | Interpretation |
|---|---|---|---|
| Serum electrolytes | Low sodium or high potassium may occur during salt wasting. | No characteristic electrolyte pattern is established. | Abnormal results suggest crisis risk but do not diagnose either condition. |
| Steroid hormone profile | Disordered adrenal and gonadal steroid pattern may be found. | No specific steroid abnormality is established. | Results require specialist interpretation and genetic confirmation. |
| Chromosomal microarray | Not expected to show 16p12.2 deletion; gene testing may be relevant. | May identify a 16p12.2 microdeletion. | A deletion supports the syndrome but phenotype remains variable. |
Prognosis comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
- Outcome
- Chronic endocrine condition; outcomes depend on recognition and hormone management, but exact prognosis is not established here.
- Factors
- Salt-wasting risk, hormone imbalance, and monitoring needs.
16p12 2 Microdeletion Syndrome C4708497
- Outcome
- Chronic condition with variable developmental and medical effects; individual outcome is not predictable from these data.
- Factors
- Degree of developmental delay, infections, and associated congenital findings.
Time frame: Lifelong, with early-childhood concerns often most apparent.
Exact diagnosis, severity, associated complications, and access to specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal crisis | A recognized potential emergency related to hormone deficiency. Not established as a feature. Urgent clinician assessment is needed for vomiting, dehydration, or collapse. |
| Recurrent infection | Not established from the supplied description. May occur in some individuals. Infection frequency and immune mechanism are not defined here. |
| Learning and developmental needs | Not a defining complication in the supplied data. Developmental delay or intellectual disability may require support. Severity varies; individualized assessment is necessary. |
Patient education highlights
- HighEmergency symptoms
Seek urgent care for vomiting, dehydration, lethargy, or collapse, especially in the enzyme deficiency.
- HighSpecialist follow-up
Endocrine care and genetic counseling differ by diagnosis and should guide testing and treatment.
- MediumVariable features
Absence of one listed feature does not exclude either rare condition.